Transcatheter aortic valve replacement: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Transcatheter | {{Short description|Minimally invasive procedure to replace a narrowed aortic valve}} | ||
{{Use dmy dates|date=October 2023}} | |||
[[File:TAVRprocedure.jpg|thumb|right|Illustration of a TAVR procedure.]] | |||
'''Transcatheter aortic valve replacement''' ('''TAVR'''), also known as '''transcatheter aortic valve implantation''' ('''TAVI'''), is a minimally invasive procedure to replace a narrowed [[aortic valve]] that fails to open properly (aortic valve stenosis). TAVR is an option for patients who are considered to be at intermediate or high risk for open-heart surgery. | |||
==Procedure== | ==Procedure== | ||
TAVR involves inserting a catheter through the [[femoral artery]] in the groin or through a small incision in the chest. The catheter is guided to the heart, where a replacement valve is deployed. The new valve is typically made from animal tissue and is mounted on a balloon-expandable or self-expanding stent. Once in place, the new valve takes over the function of regulating blood flow from the heart to the [[aorta]]. | |||
==Indications== | ==Indications== | ||
TAVR is | TAVR is primarily indicated for patients with severe aortic stenosis who are at increased risk for complications from traditional open-heart surgery. It is also considered for patients who are not candidates for surgery due to other medical conditions. The decision to perform TAVR is based on a comprehensive evaluation by a heart team, including cardiologists and cardiac surgeons. | ||
==Risks | ==Benefits and Risks== | ||
The benefits of TAVR include a shorter recovery time compared to open-heart surgery, reduced hospital stay, and improved quality of life. However, TAVR carries risks such as bleeding, vascular complications, stroke, and the need for a permanent pacemaker. Long-term durability of the valve is also a consideration. | |||
==History== | ==History== | ||
The first TAVR procedure was performed in 2002 by | The first successful TAVR procedure was performed in 2002 by French cardiologist [[Alain Cribier]]. Since then, the procedure has evolved significantly, with improvements in valve design and delivery systems. TAVR has become a widely accepted treatment for aortic stenosis, with numerous clinical trials demonstrating its safety and efficacy. | ||
==Related pages== | |||
* [[Aortic stenosis]] | |||
* [[Heart valve replacement]] | |||
* [[Cardiac surgery]] | |||
==References== | |||
{{Reflist}} | |||
== | ==External links== | ||
* [ | * [https://www.heart.org/en/health-topics/heart-valve-problems-and-disease/heart-valve-surgery/transcatheter-aortic-valve-replacement-tavr American Heart Association: Transcatheter Aortic Valve Replacement (TAVR)] | ||
[[Category:Cardiac surgery]] | |||
[[Category:Cardiac | [[Category:Interventional cardiology]] | ||
[[Category: | |||
Revision as of 16:13, 9 February 2025
Minimally invasive procedure to replace a narrowed aortic valve
Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly (aortic valve stenosis). TAVR is an option for patients who are considered to be at intermediate or high risk for open-heart surgery.
Procedure
TAVR involves inserting a catheter through the femoral artery in the groin or through a small incision in the chest. The catheter is guided to the heart, where a replacement valve is deployed. The new valve is typically made from animal tissue and is mounted on a balloon-expandable or self-expanding stent. Once in place, the new valve takes over the function of regulating blood flow from the heart to the aorta.
Indications
TAVR is primarily indicated for patients with severe aortic stenosis who are at increased risk for complications from traditional open-heart surgery. It is also considered for patients who are not candidates for surgery due to other medical conditions. The decision to perform TAVR is based on a comprehensive evaluation by a heart team, including cardiologists and cardiac surgeons.
Benefits and Risks
The benefits of TAVR include a shorter recovery time compared to open-heart surgery, reduced hospital stay, and improved quality of life. However, TAVR carries risks such as bleeding, vascular complications, stroke, and the need for a permanent pacemaker. Long-term durability of the valve is also a consideration.
History
The first successful TAVR procedure was performed in 2002 by French cardiologist Alain Cribier. Since then, the procedure has evolved significantly, with improvements in valve design and delivery systems. TAVR has become a widely accepted treatment for aortic stenosis, with numerous clinical trials demonstrating its safety and efficacy.
Related pages
References
<references group="" responsive="1"></references>
